Leerink Partnrs Reduces Earnings Estimates for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of AstraZeneca in a note issued to investors on Monday, November 18th. Leerink Partnrs analyst A. Berens now expects that the company will earn $5.28 per share for the year, down from their prior estimate of $5.31. The consensus estimate for AstraZeneca’s current full-year earnings is $4.07 per share. Leerink Partnrs also issued estimates for AstraZeneca’s FY2026 earnings at $6.05 EPS.

A number of other research analysts have also recently issued reports on AZN. TD Cowen increased their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

Shares of AZN opened at $63.80 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a 50-day simple moving average of $74.34 and a 200-day simple moving average of $78.06. The company has a market capitalization of $197.82 billion, a PE ratio of 30.53, a P/E/G ratio of 1.17 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share.

Hedge Funds Weigh In On AstraZeneca

A number of institutional investors have recently made changes to their positions in the stock. Rehmann Capital Advisory Group boosted its stake in shares of AstraZeneca by 1.8% during the third quarter. Rehmann Capital Advisory Group now owns 10,027 shares of the company’s stock valued at $788,000 after acquiring an additional 175 shares during the last quarter. Toronto Dominion Bank lifted its holdings in AstraZeneca by 15.5% in the 3rd quarter. Toronto Dominion Bank now owns 17,929 shares of the company’s stock valued at $1,397,000 after purchasing an additional 2,408 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in shares of AstraZeneca by 4.1% during the 3rd quarter. Coldstream Capital Management Inc. now owns 26,777 shares of the company’s stock worth $2,086,000 after purchasing an additional 1,050 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of AstraZeneca by 0.3% during the third quarter. Geode Capital Management LLC now owns 493,447 shares of the company’s stock worth $38,444,000 after buying an additional 1,269 shares in the last quarter. Finally, Groupama Asset Managment raised its position in shares of AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after buying an additional 101,225 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.